fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Anastrozole

All products: general benefit

Anastrozole · DIN 02351218 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Anastrozole · DIN 02351218 Manufacturer: Accord Healthcare Inc.; listing date 2012-12-21 Health Canada: Marketed since 2014-10-23 · brand ACH-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02351218)

Source record
DIN 02351218: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id ACH Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02351218 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83640
Interchangeable products
Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended December 29, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351218
Shortage record checked October 6, 2026

Anastrozole · DIN 02442736 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Anastrozole · DIN 02442736 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2015-07-22 · brand ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442736)

Source record
DIN 02442736: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SAI Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442736 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92706
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442736
Shortage record checked October 6, 2026

Anastrozole · DIN 02529904 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Anastrozole · DIN 02529904 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-08-31 Health Canada: Marketed since 2025-05-29 · brand ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529904)

Source record
DIN 02529904: Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SIV Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529904 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101913
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended June 9, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529904
Shortage record checked October 6, 2026

Apo-Anastrozole · DIN 02374420 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Anastrozole · DIN 02374420 Manufacturer: Apotex Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-25 · brand APO-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02374420)

Source record
DIN 02374420: Apo-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02374420 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85968
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended January 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02374420
Shortage record checked October 6, 2026

Arimidex · DIN 02224135 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists Arimidex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ARIMIDEX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Arimidex · DIN 02224135 Manufacturer: AstraZeneca; listing date 1996-12-19 Health Canada: Marketed since 2002-01-25 · brand ARIMIDEX · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02224135)

Source record
DIN 02224135: Arimidex Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id AZC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $6.3557; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02224135 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43395
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224135
Shortage record checked October 6, 2026

Co Anastrozole · DIN 02394898 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Anastrozole · DIN 02394898 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-12-21 Health Canada: Marketed since 2020-01-21 · brand TEVA-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Co Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394898)

Source record
DIN 02394898: Co Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id COB Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394898 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88004
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended January 26, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394898
Shortage record checked October 6, 2026

Jamp Anastrozole Tablets · DIN 02540584 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Anastrozole Tablets · DIN 02540584 Manufacturer: Jamp Pharma Corporation; listing date 2026-09-29 Health Canada: Marketed since 2025-09-29 · brand JAMP ANASTROZOLE TABLETS · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Anastrozole Tablets: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540584)

Source record
DIN 02540584: Jamp Anastrozole Tablets Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id JPC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540584 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102927
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02540584
Shortage record checked October 6, 2026

Jamp-Anastrozole · DIN 02339080 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Anastrozole · DIN 02339080 Manufacturer: Jamp Pharma Corporation; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand JAMP-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02339080)

Source record
DIN 02339080: Jamp-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id JPC Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02339080 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82471
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02339080
Shortage record checked October 6, 2026

Mar-Anastrozole · DIN 02379562 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Anastrozole · DIN 02379562 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand MAR-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02379562)

Source record
DIN 02379562: Mar-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id MAR Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02379562 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86544
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended October 11, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379562
Shortage record checked October 6, 2026

Mint-Anastrozole · DIN 02393573 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Anastrozole · DIN 02393573 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2026-06-26 · brand MINT-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393573)

Source record
DIN 02393573: Mint-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id MIN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393573 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87879
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: active shortage (reported January 27, 2025, estimated to end October 31, 2026, last updated September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393573
Shortage record checked October 6, 2026

Nat-Anastrozole · DIN 02417855 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Anastrozole · DIN 02417855 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30 Health Canada: Marketed since 2015-02-03 · brand NAT-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nat-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02417855)

Source record
DIN 02417855: Nat-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id NAT Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02417855 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90247
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417855
Shortage record checked October 6, 2026

PMS-Anastrozole · DIN 02320738 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Anastrozole · DIN 02320738 Manufacturer: Pharmascience Inc.; listing date 2012-12-21 Health Canada: Marketed since 2012-10-25 · brand PMS-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02320738)

Source record
DIN 02320738: PMS-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id PMS Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02320738 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80614
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: active shortage (reported September 19, 2025, last updated September 22, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320738
Shortage record checked October 6, 2026

Riva-Anastrozole · DIN 02392259 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Anastrozole · DIN 02392259 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2025-12-29 · brand RIVA-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Riva-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392259)

Source record
DIN 02392259: Riva-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id RIA Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392259 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87753
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: active shortage (reported not recorded, last updated May 22, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392259
Shortage record checked October 6, 2026

Sandoz Anastrozole · DIN 02338467 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Anastrozole · DIN 02338467 Manufacturer: Sandoz Canada Inc.; listing date 2012-09-28 Health Canada: Marketed since 2012-07-26 · brand SANDOZ ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02338467)

Source record
DIN 02338467: Sandoz Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id SDZ Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02338467 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82412
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: resolved shortage (ended April 16, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02338467
Shortage record checked October 6, 2026

Taro-Anastrozole · DIN 02365650 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Anastrozole · DIN 02365650 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2013-01-29 Health Canada: Marketed since 2012-10-25 · brand TARO-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Taro-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365650)

Source record
DIN 02365650: Taro-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id TAR Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365650 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85053
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522
Shortage status: resolved shortage (ended June 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365650
Shortage record checked October 6, 2026

Med-Anastrozole · DIN 02379104 · 1 mg · tablet

General benefitDormant since March 23, 2018 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Anastrozole · DIN 02379104 Manufacturer: Generic Medical Partners Inc.; listing date 2012-12-21 Health Canada: Dormant since 2018-03-23 · brand MED-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Generic medical partners inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Med-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02379104)

Source record
DIN 02379104: Med-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id GMP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02379104 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86499
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379104
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since March 23, 2018 — choose a marketed DIN from the same-category list.

CCP-Anastrozole · DIN 02458799 · 1 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2023 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
CCP-Anastrozole · DIN 02458799 Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2017-12-21 Health Canada: Cancelled post market since 2023-08-03 · brand CCP-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Cellchem pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

CCP-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02458799)

Source record
DIN 02458799: CCP-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id CCP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02458799 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94594
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Ran-Anastrozole · DIN 02328690 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458799
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2023 — choose a marketed DIN from the same-category list.

Ran-Anastrozole · DIN 02328690 · 1 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-01-22 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Anastrozole · DIN 02328690 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-12-21 Health Canada: Cancelled post market since 2024-01-22 · brand RAN-ANASTROZOLE · ATC L02BG03 ANASTROZOLE · form Tablet · route Oral · ingredients ANASTROZOLE 1 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Anastrozole: Formulary list price $0.95 per unit (the source does not state the unit; exact figure $0.9522). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02328690)

Source record
DIN 02328690: Ran-Anastrozole Raw flags: sec3=Y Item: 100000109; group id 144; item number 0243; lccId None; manufacturer id RAN Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.9522; ministry $0.9522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02328690 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81420
Interchangeable products
Anastrozole · DIN 02351218 · $0.9522 Anastrozole · DIN 02442736 · $0.9522 Anastrozole · DIN 02529904 · $0.9522 Apo-Anastrozole · DIN 02374420 · $0.9522 Arimidex · DIN 02224135 · $0.9522 CCP-Anastrozole · DIN 02458799 · $0.9522 Co Anastrozole · DIN 02394898 · $0.9522 Jamp Anastrozole Tablets · DIN 02540584 · $0.9522 Jamp-Anastrozole · DIN 02339080 · $0.9522 Mar-Anastrozole · DIN 02379562 · $0.9522 Med-Anastrozole · DIN 02379104 · $0.9522 Mint-Anastrozole · DIN 02393573 · $0.9522 Nat-Anastrozole · DIN 02417855 · $0.9522 PMS-Anastrozole · DIN 02320738 · $0.9522 Riva-Anastrozole · DIN 02392259 · $0.9522 Sandoz Anastrozole · DIN 02338467 · $0.9522 Taro-Anastrozole · DIN 02365650 · $0.9522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328690
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L02B, L02BG): coverage varies; not interchangeable

  • Exemestane (Aromasin): general benefit
  • Letrozole (Femara): general benefit
  • Abiraterone (Zytiga): general benefit
  • Bicalutamide (Casodex): general benefit, not a benefit
  • Degarelix (Firmagon): general benefit
  • Flutamide (Euflex): general benefit, not a benefit

3 more in the class list below

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ARIMIDEX (anastrozole) is indicated for: • the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Approval is based on superior disease-free survival for ARIMIDEX in comparison to tamoxifen. However, overall survival was not significantly different between the two treatments (see 14 CLINICAL TRIALS). • hormonal treatment of advanced breast cancer in postmenopausal women. 1.1 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for pediatric use for ARIMIDEX as safety and efficacy have not been established in this group of patients. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00078111.PDF PM date: AUG 1, 1996 Source product: ARIMIDEX; DIN 02224135; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Mint-Anastrozole · DIN 02393573 Shortage status: active shortage (reported 2025-01-27, estimated to end 2026-10-31, last updated 2026-09-23); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393573

Check this DIN again

PMS-Anastrozole · DIN 02320738 Shortage status: active shortage (reported 2025-09-19, last updated 2025-09-22); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320738

Check this DIN again

Riva-Anastrozole · DIN 02392259 Shortage status: active shortage (reported not recorded, last updated 2024-05-22) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392259

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)